Hamad Azam
Pulmonary Disease · Cedar Rapids, IANPI 1861602542
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 96.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $6,246, more than ten times the $189 reported in 2019.
Across 29 payments — averaging $322.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Johnson & Johnson$137
- ERBE USA Inc$47
- AbbVie$41
- Conmed Corporation$33
- Getinge USA Sales, LLC$24
- plus $16 from 1 others
What the payments were for
- Speaking & faculty fees$4,50048%
- Travel & lodging$2,76130%
- Food & beverage$5686%
- Education$1,51616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $9,047 |
| Johnson & Johnson | 1 | $137 |
| ERBE USA Inc | 2 | $47 |
| AbbVie | 3 | $41 |
| Conmed Corporation | 1 | $33 |
| Getinge USA Sales, LLC | 1 | $24 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,649
- MONARCH$137
How this compares
$9,345 in reported general payments places this provider in the 80th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 308 | $229,983 |
| Breo ElliptaFluticasone/Vilanterol | 299 | $151,329 |
| Incruse ElliptaUmeclidinium Bromide | 143 | $60,076 |
| Dupixent PenDupilumab | 13 | $59,326 |
| Spiriva HandihalerTiotropium Bromide | 67 | $54,847 |
| Spiriva RespimatTiotropium Bromide | 70 | $44,699 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $44,145 |
| Arnuity ElliptaFluticasone Furoate | 150 | $40,858 |
| DuleraMometasone/Formoterol | 78 | $32,054 |
| SymbicortBudesonide/Formoterol Fumarate | 105 | $31,056 |
| XareltoRivaroxaban | 22 | $29,613 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $29,146 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $28,866 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,315 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $23,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $137 | $29,61322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Cedar Rapids
- Syed ShahCedar Rapids$12K
- Vijaya GogineniCedar Rapids$5K
- Hafiz HashmiCedar Rapids$4K
- Giovanni Cordoba SolisCedar Rapids$2K
- Brian LindsayCedar Rapids$793
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.